Parallel Bio Secures $21M Series A to Power Next-Gen Immunotherapy with a Human Immune System in a Dish

Parallel Bio is excited to announce a landmark funding milestone, having successfully raised $21,000,000 to accelerate our groundbreaking mission in drug discovery and immunotherapy development. As pioneers in recreating a human immune system within a controlled laboratory environment—what we call an "immune system in a dish"—we are transforming the way scientists predict patient responses to novel treatments. This innovative approach not only bridges the gap between traditional animal models and human clinical trials but also paves the way for personalized therapies designed to work more effectively for patients. The recent infusion of capital reinforces our commitment to pushing the boundaries of biomedical research and optimizing therapeutic strategies. With these funds, Parallel Bio aims to expand its research capabilities, optimize its state-of-the-art platform, and accelerate the discovery of drugs and immunotherapies that are more likely to succeed in clinical settings. Investment will be funneled toward enhancing our laboratory infrastructure, increasing our scientific talent pool, and deepening our strategic collaborations with academic and industry partners. By further refining our immune system in a dish technology, we are not only reducing the risks associated with pre-clinical development but also significantly cutting down the time it takes to bring life-saving treatments from the lab bench to the patient’s bedside. This milestone underscores our belief that innovation in early-stage science can lead to breakthroughs that profoundly improve patient outcomes. At Parallel Bio, every dollar raised is a step forward in our vision to reinvent drug discovery, ultimately offering hope and enhanced treatment strategies to communities worldwide. We are grateful for the trust and support from our investors and are eager to embark on this exciting journey toward a healthier future.